Why the study?
Treatment of CHF with LV systolic dysfunction and severe AS is challenging, and periprocedural outcomes of TAVR needed comparison between patients with EF ≤20% versus EF >20% to ≤40%.
Does TAVR have similar periprocedural and intermediate-term outcomes in patients with severe aortic stenosis and EF ≤ 20% compared to those with EF > 20% to ≤ 40%?
Does TAVR have similar periprocedural and intermediate-term outcomes in patients with severe aortic stenosis and EF ≤ 20% compared to those with EF > 20% to ≤ 40%?
TAVR is feasible and has similar periprocedural and 1-year outcomes in patients with severe AS and EF ≤ 20% compared to those with EF 21-40%, though it requires more intraprocedural hemodynamic support.
No takes yet. Share an insight, caveat, or question.
Supports TAVR feasibility in EF ≤20%; leaves open need for randomized confirmation of outcomes.
Kodra et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: